Humacyte (HUMAW) Projected to Post Quarterly Earnings on Thursday

Humacyte (NASDAQ:HUMAW) is anticipated to issue its results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.1317) per share and revenue of $1.3490 million for the quarter.

Humacyte Price Performance

Humacyte stock opened at $0.10 on Tuesday. Humacyte has a twelve month low of $0.08 and a twelve month high of $0.99. The company’s 50-day moving average price is $0.11 and its two-hundred day moving average price is $0.16.

Humacyte Company Profile

Humacyte, Inc (NASDAQ:HUMAW) is a clinical-stage biotechnology company specializing in the development and manufacture of human acellular vessels (HAVs). These off-the-shelf, bioengineered vascular conduits are designed to serve as living implants for patients requiring vascular access, including those undergoing hemodialysis, as well as for peripheral artery disease and vascular trauma. Humacyte’s proprietary tissue-engineering platform leverages human vascular cells cultured on biodegradable scaffolds, which are subsequently decellularized to produce durable, non-immunogenic vessels that support natural tissue regeneration.

Founded in 2007 and headquartered in Durham, North Carolina, Humacyte has advanced its lead candidate, the HAV, through multiple clinical trials in the United States and Europe.